Catalog No: OKVC00001
Size:96 Wells
Price: $550.00
SKU
OKVC00001
Availability: Please Inquire
Contact Us:
- Toll Free: 888-880-0001
- Phone: 858-552-6979
- Email: info@avivasysbio.com
Shipping Info:
- $55: Antibody & Protein in US
- $55 + $25/Kit in US
- Contact us for international orders.
Datasheets/Manuals | Click here to download product manual. As variation between lots may occur, always reference the lot-specific manual received with each kit. |
---|
Predicted Species Reactivity | Human | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Application | ELISA | ||||||||||||||||||||
ELISA Kit Principle | Aviva Systems Biology Covid-19 IgA ELISA Kit (OKVC00001) is a two-step incubation, solid-phase ELISA assay in which microwell strips were coated with SARS-CoV-2 recombinant antigens. The serum/plasma sample is added, and during the first incubation, all anti SARS-CoV-2 antibodies if present in the specimen will bind to the recombinant antigens precoated on the wells. After washing out all the other substances of the specimen SARS-CoV-2 specific IgA antibodies bound to the solid phase are detected by the addition of anti human IgA conjugated to the enzyme horseradish peroxidase (HRP) to form an antigen- antibody-antibody-HRP enzyme complex on the microwell surface. Upon addition of TMB substrate, the HRP enzyme converts it into a blue color signal. The intensity of the color is directly proportional to the concentration of SARS-Cov-2 IgA antibodies in the sample. | ||||||||||||||||||||
ELISA Kit Reproducibility | Intra-lot Repeatability: Three Covid-19 IgA positive sera were run on one lot of Covid-19 IgG, CV < 11% Inter-lot Reproducibility: Three Covid-19 IgA positive sere were run on three of Covid-19 IgG, CV < 19% | ||||||||||||||||||||
ELISA Kit Component |
| ||||||||||||||||||||
Reconstitution and Storage | Store as indicated in product manual. | ||||||||||||||||||||
Sample Type | Serum, Plasma | ||||||||||||||||||||
Sensitivity | 76/77 = 98.7% (95%) credibility interval: (94.22%~99.99%) | ||||||||||||||||||||
Reference | 1. Pr. Yazdan Yazdanpanah, Chair of GloPID R https://www.glopid-r.org @GloPID_R, 2019 Novel Coronavirus Global Research and Innovation Forum: Towards a Research Roadmap. 2. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimensexternal icon. JAMA. Published online March 11, 2020. DOI:10.1001/jama.2020.3786. 3. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in Chinaexternal icon. N Engl J Med. February 28, 2020. DOI: 10.1056/NEJMoa2002032. 4. Kakimoto K, Kamiya H, Yamagishi T, et al. Initial Investigation of Transmission of COVID-19 Among Crew Members During Quarantine of a Cruise Ship - Yokohama, Japan, February 2020. MMWR Morb Mortal Wkly Rep. ePub: March 17, 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6911e2external iconexternal icon. | ||||||||||||||||||||
Specificity | 169/169 = 100% (95%) credibility interval: (96.72%~99.99%) | ||||||||||||||||||||
Assay Info | Qualitative two-step solid-phase ELISA | ||||||||||||||||||||
Intended Use | SARS-CoV-2 IgA ELISA is an enzyme-linked immunosorbent assay for the qualitative detection of IgA-class antibodies to SARS-CoV-2 virus in human serum or plasma. | ||||||||||||||||||||
Warning | The test kit does not contain any viable infectious agents. However all samples must be considered as potentially infectious.
| ||||||||||||||||||||
Introduction | Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by infection with the SARS-CoV-2 virus(1,2). Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In severe cases, infection can cause pneumonia, severe acute respiratory syndrome (SARS), kidney failure and death(3). Coronaviruses (CoV) are a large family of RNA viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARSCoV). The 2019 Novel Coronavirus, formerly known as 2019-nCoV and now known as SARS-COV-2, is a new strain of coronavirus that was first identified during an outbreak in Wuhan, China which started in December 2019(4). |
Gene Symbol | SARS-COV-2 |
---|
- Protocol:
- Reconstitution & Storage Instructions
- Western Blotting/Immunoblotting (WB/IB) Protocol
- Immunohistochemistry (IHC) Protocol
- Immunocytochemistry (ICC) Protocol
- Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol
- Blocking Peptide Competition Protocol (BPCP)
- Immunoprecipitation (IP) Protocol
- Antibody Array (AA) Protocol
- Tips Information:
-
See our General FAQ page.
Write Your Own Review